"United States Pharmaceuticals & Healthcare Report Q3 2011" now available at Fast Market Research

New Healthcare market report from Business Monitor International: "United States Pharmaceuticals & Healthcare Report Q3 2011"
Spread the Word
Listed Under



Massachusetts - US

July 6, 2011 - PRLog -- BMI View: The US pharmaceutical market is a refuge for the leading drugmakers. It is highly unlikely that punitive price controls, as witnessed across Europe over the past two years, will be introduced. The market is also underpinned by political stability, unlike many emerging markets, and a recovering economy. Healthcare reform places downward pressure on margins and patent expiries will compress headline growth. Unique attributes include a highly liberalised advertising environment and a culture of over-medication.

Headline Expenditure Projections

*  Pharmaceuticals: US$327.03bn in 2010 to US$331.68bn in 2011; +1.4% growth in local currency terms. Our forecast has been revised down moderately from Q211 due to analyst intervention.
 *  Healthcare: US$2,473bn in 2010 to US$2,576bn in 2011; 4.2% growth in local currency terms. Our forecast remains unchanged.
 *  Medical devices:US$127.6bn in 2010 to US$133.1bn in 2011; 4.4% growth in local currency terms. Our forecast remains unchanged.

Full Report Details at
- http://www.fastmr.com/prod/204776_united_states_pharmaceu...

Business Environment Rating: The US's Industry Rewards score in BMI's BERs increased from 70 in Q211 to 73 in Q311. New cuts on payroll taxes, the extension of unemployment benefits and the 2001/2003 tax cuts are a game changer for the US's economic outlook in 2011. We have raised our forecast for real GDP growth in 2011 from 2.0% to 2.8% and see modest upside risks. Our overall view is that private consumption will be stronger in 2011 than previously expected, though the overall rate of expansion will still be weaker compared with previous recoveries from recession.

Key Trends & Developments

*  Teva has announced a US$6.8bn takeover of Cephalon, a US-based innovative drugmaker with net sales of US$2.81bn in 2010. The purchase continues the Israeli company's rapid expansion through M&A that it hopes will facilitate a doubling in net sales by 2015.
 *  In May 2011, the Federal Trade Commission (FTC) stated that the number of deals struck between branded and generic drugmakers to keep generic competition off the US market rose by 60% in 2010.

BMI Economic View: Our basic view is that despite the current challenges to the global economic outlook, the US recovery will continue, but remain at a very sub-par pace compared with previous recoveries. The key risk over the coming quarters is the potential for an oil price spike amid unrest in the Middle East and North Africa (MENA) pushing up domestic energy prices and stifling the consumer recovery.

BMI Political View: The first US federal government shutdown since 1996 was only narrowly averted, with congressional Republicans and Democrats reaching a last-minute accord to extend government spending beyond April 8. The episode is emblematic of the friction between the two major parties over the rise in government spending and how to deal with it. On a broader scale, it is clear that the political theme in Washington until and potentially beyond elections in 2012 will be obstruction and disagreement.

Partial Table of Contents:

SWOT Analysis
- US Pharmaceuticals And Healthcare Industry SWOT
- US Political SWOT
- US Economic SWOT
- US Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas - Regional Business Environment Ratings, Q311
- Rewards
- Risks
US - Market Summary
Regulatory Regime
- Recent Regulatory Developments
- Innovative Drug Regulations
- Table: CDER Approval Times For Priority And Standard NDAs And New BLAs*
- Table: CDER NME and New BLA Approvals: May 2009-April 2010
- Generic Drug Regulations
- Table: CDER Approval Times For Original Generic Drugs
- Table: First-time ANDA Generic Drug Approvals
- Biosimilar Regulations
- OTC Medicine Regulations
- Medical Device Regulations
- Table: US FDA Medical Device Approvals May 2009-April 2010
- Promotion Regulations
- Intellectual Property (IP) Regulations
- Table: PhRMA Special 301 Submissions 2010
- Pricing & Reimbursement Environment
- Part D
Industry Developments
- Epidemiology
- Healthcare Sector
- Research and Development Sector
- Table: Biotechnology Medicines In Development By Product Category
- Clinical Trials
- Contract/Clinical Research Organisations
- Medical Device Industry
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Macroeconomic Forecast Scenario
- Table: United States - GDP Contribution To Growth
- Table: United States - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Top 10 Therapeutic Classes By Sales (US$bn)
- Top 10 Therapeutic Classes By Dispensed Prescriptions (mn)
- Patented Product Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=2047...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:***@fastmr.com Email Verified
Tags:Pharmaceutical, Medicine, Healthcare, Prescriptions, Health, Insurance, Globally, Patients, Conditions, Medicines
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share